64 #ScientificSessions26 Listings current as of Oct. 14, 2026. Please view the Mobile Meeting Guide App for updates. These events are located in the Science & Technology Hall. Industry Programming Industry Events Saturday, Nov. 7 When Could CARDAMYST, the First and Only FDA-Approved Self-Administered Treatment for PSVT in Adults, Be Used in a Healthcare Professional’s Practice? 9:30–10:15 a.m. Heart Theater 1 SUPPORTER: Milestone Pharmaceuticals, Inc. Putting the Pieces Together in ATTR-CM: A Practical Approach 9:30–10:15 a.m. Learning Studio 3 SUPPORTER: BridgeBio Pharma, Inc. Empowering Champions: Cardiology’s Untapped Role in Stroke Prevention 9:30–10:15 a.m. Learning Studio 4 SUPPORTER: Medtronic, Inc. Incretin-Based Therapies and the CKM Framework: Practical Considerations for Cardiovascular Practice 9:45–10:15 a.m. CardioTalk 2 SUPPORTER: Eli Lilly and Company Beyond Medication: Advancing Hypertension Care With the Symplicity™ Blood Pressure Procedure 11:15 a.m.–Noon Heart Theater 1 SUPPORTER: Medtronic, Inc. Aldosterone Dysregulation as a Driver of Uncontrolled and Resistant Hypertension, and CKM Risk: Cardiology, Endocrinology and Nephrology Clinical Perspectives 11:15 a.m.–Noon Heart Theater 2 SUPPORTER: Mineralys Therapeutics Lp(a) Uncovered: Turning Inherited Risk Into Clinical Insight 11:15 a.m.–Noon Learning Studio 1 SUPPORTER: Amgen Inc. Redemplo® (plozasiran): A Treatment to Lower Triglycerides for Adults With Familial Chylomicronemia Syndrome (FCS) 11:15 a.m.–Noon Learning Studio 2 SUPPORTER: Arrowhead Pharmaceuticals, Inc. Advancing the ATTR-CM Journey Across the Care Continuum 11:15 a.m.–Noon Learning Studio 3 SUPPORTER: Pfizer Inc. A Change of Heart: Rethinking Cardiovascular Care With GLP-1RAs 11:15 a.m.–Noon Learning Studio 4 SUPPORTER: Novo Nordisk, Inc. Cracking The Code: Uncover a Hidden Driver of Resistant Hypertension 11:15 a.m.–Noon Learning Studio 5 SUPPORTER: Corcept Therapeutics Inc. Chasing Long-Term Cholesterol Control: Persistent Challenges and a Potential Role for One-Time Gene Editing Approaches 11:30 a.m.–12:45 p.m. Industry Room N427D SUPPORTER: Eli Lilly and Company Recurrent Pericarditis: Experts Perspectives on Disease Diagnosis and Management 12:30–1:15 p.m. Heart Theater 1 SUPPORTER: Kiniksa Pharmaceuticals Corporation What We Don’t Do, What We Don’t See, What Comes Next: Device Therapy in Heart Failure 12:30–1:15 p.m. Heart Theater 2 SUPPORTER: Medtronic, Inc. A Novel Aldosterone-Targeted Treatment for Patients With Uncontrolled Hypertension 12:30–1:15 p.m. Learning Studio 1 SUPPORTER: AstraZeneca Unaddressed Risks: RAAS Dysregulation & the Role of Aldosterone in HF 12:30–1:15 p.m. Learning Studio 2 SUPPORTER: Boehringer Ingelheim Pharmaceuticals, Inc. CRISPR-Based Gene Editing: Expanding Horizons in Cardiac Care 12:30–1:15 p.m. Learning Studio 3 SUPPORTER: Intellia Therapeutics, Inc. Closing the Gap: Advancing Guideline-Directed Lipid Management and Treatment Intensification for High-Risk Patients 12:30–1:15 p.m. Learning Studio 4 SUPPORTER: Novartis Pharmaceutical Corporation Implementation in Action: Closing the Gap in ASCVD 12:30–1:15 p.m. Learning Studio 5 SUPPORTER: Amgen Inc. Obstructive HCM: Translating Evidence Into Practice 12:30–1:15 p.m. CardioTalk 2 SUPPORTER: Bristol Myers Squibb Advancing Lp(a) Care Through Shared Decision-Making 1:30–2 p.m. CardioTalk 2 SUPPORTER: (Heart) Implementation Science (QORA) Beyond Traditional HCM: Understanding Cardiac Disease Progression in Friedreich Ataxia 1:45–2:30 p.m. Heart Theater 1 SUPPORTER: Lexeo Therapeutics, Inc. These events are not part of the official Scientific Sessions Conference 2026 as planned by the American Heart Association Committee on Scientific Sessions Programming.
RkJQdWJsaXNoZXIy MjI2NjI=